Peripheral Neuritis Treatment Market Report 2026

The peripheral neuritis treatment market size has grown strongly in recent years. It will grow from $1.93 billion in 2025 to $2.03 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to high prevalence of diabetic neuropathy, limited availability of targeted therapies, reliance on conventional analgesics and anticonvulsants, growing awareness of peripheral neuritis symptoms, fragmented healthcare infrastructure.

The peripheral neuritis treatment market size is expected to see steady growth in the next few years. It will grow to $2.44 billion in 2030 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to advancements in pharmacological therapies, increasing adoption of non-pharmacological therapies such as tens and acupuncture, rising use of online and retail pharmacies, growing focus on lifestyle and dietary modifications, expansion of diabetic care programs and specialized clinics. Major trends in the forecast period include increasing adoption of ai-based peripheral neuritis monitoring tools, rising integration of digital health platforms for peripheral neuropathy management, growing use of genomic and precision medicine approaches in peripheral neuritis, increasing implementation of iot-enabled patient monitoring devices, rising development of smart manufacturing for peripheral neuritis therapeutics.

The increasing prevalence of diabetes is expected to drive the growth of the peripheral neuritis treatment market in the coming years. Diabetes is a chronic condition in which the body is unable to effectively regulate blood glucose levels. The rising incidence of diabetes is linked to factors such as sedentary lifestyles, unhealthy eating habits, obesity, aging populations, and genetic susceptibility. Peripheral neuritis treatments play a vital role in supporting individuals with diabetes by alleviating nerve pain, reducing inflammation, and improving nerve function, which helps enhance quality of life and prevent further complications. For instance, in 2024, according to the International Diabetes Federation, a Belgium-based diabetes research organization, the number of adults aged 20 to 79 years living with diabetes worldwide is projected to rise from approximately 589 million in 2024 to 853 million by 2050, reflecting a 45% increase. Therefore, the growing prevalence of diabetes is contributing to the expansion of the peripheral neuritis treatment market.

Major companies operating in the peripheral neuritis treatment market are concentrating on the development of advanced therapeutic options such as magnetic peripheral nerve stimulation to improve nerve regeneration and reduce neuropathic pain. Magnetic peripheral nerve stimulation is a non-invasive neuromodulation technique that uses magnetic fields to stimulate peripheral nerves, helping manage pain, promote nerve regeneration, and improve motor function in conditions including neuropathy and musculoskeletal disorders. For example, in January 2024, Neuralace Medical Inc., a US-based medical device manufacturer, announced that its Axon Therapy based on magnetic peripheral nerve stimulation received approval from the US Food and Drug Administration for the treatment of chronic painful diabetic neuropathy. This therapy offers a rapid, painless, and non-invasive approach to pain relief. Clinical studies demonstrated a responder rate of 72.3% at day 30 and 81.4% at day 90, highlighting its effectiveness in reducing pain and numbness. This approval represents a significant advancement in pain management by providing patients with an alternative to traditional drug-based treatments without associated medication side effects.

In October 2024, Alkem Laboratories Limited, an India-based pharmaceutical company, entered into a partnership with Sonnet BioTherapeutics to bring an innovative neuropathy treatment to the Indian market. Through this collaboration, the companies aim to develop, manufacture, and commercialize Sonnet’s drug candidate SON-080 for the treatment of diabetic peripheral neuropathy in India. Sonnet BioTherapeutics is a US-based biotechnology company with a primary focus on oncology.

Major companies operating in the peripheral neuritis treatment market are Pfizer Inc., Johnson & Johnson (J&J), AstraZeneca Plc, Novartis AG, GSK plc, Takeda Pharmaceuticals & Co. Ltd., Eli Lilly and Co., Mallinckrodt Pharmaceuticals plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr Reddys Laboratories Ltd., Cipla Inc., Amneal Pharmaceuticals LLC, Lupin Ltd., Daiichi Sankyo Co. Ltd., Glenmark Pharmaceuticals Ltd., Cadila Pharmaceuticals Ltd.

North America was the largest region in the peripheral neuritis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peripheral neuritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the peripheral neuritis treatment market by raising the cost of imported pharmacological agents, analgesics, and advanced monitoring devices, particularly affecting regions in North America and Europe. This has temporarily slowed the uptake of new therapies across hospitals, retail pharmacies, and online distribution channels. However, the tariffs have encouraged local manufacturing, promoted cost-efficient alternatives, and accelerated innovation in non-pharmacological therapies for peripheral neuritis.

The peripheral neuritis treatment market research report is one of a series of new reports that provides peripheral neuritis treatment market statistics, including peripheral neuritis treatment industry global market size, regional shares, competitors with a peripheral neuritis treatment market share, detailed peripheral neuritis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral neuritis treatment industry. This peripheral neuritis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peripheral neuritis is a condition characterized by inflammation or damage to peripheral nerves, resulting in symptoms such as pain, weakness, numbness, and tingling. It is commonly caused by factors including diabetes, infections, exposure to toxins, or nutritional deficiencies. Treatment typically includes medications, physical therapy, lifestyle changes, and management of underlying conditions to relieve symptoms and improve nerve function.

The primary treatment approaches for peripheral neuritis include pharmacological and non-pharmacological therapies. Pharmacological treatments involve the use of medications such as pain relievers, anticonvulsants, and antidepressants to manage symptoms by reducing pain transmission and supporting nerve function. These medications are categorized into antidepressants, anticonvulsants, local anesthetics, analgesics, steroids, and other drug classes. They are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and drug stores, and are used across applications including diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, idiopathic peripheral neuropathy, and others.

The peripheral neuritis treatment market consists of revenues earned by entities by providing services such as pharmacological treatment, physical therapy and rehabilitation, nutritional and dietary support, lifestyle management and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral neuritis treatment market also includes sales of pain relievers, antidepressants, anticonvulsants, and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.